Gilead to buy cancer drugmaker Immunomedics for $21B
Bio Pharma Dive
SEPTEMBER 13, 2020
The acquisition caps an active year of dealmaking for Gilead, which under CEO Daniel O'Day aims to become as well known for its cancer drugs as its HIV and hepatitis C medicines.
Let's personalize your content